Osteo-Guard by Douglas Laboratories — Ingredients, Evidence & Safety

🟢 100/100

This product looks safe

No ingredients exceed tolerable upper intake levels
50% of ingredients have research evidence

A Label Compliance Grade

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

1 Tablet(s) Serving Size

120 Servings

Other Combinations Product Type

50% Evidence Coverage

Supplement Facts — Evidence Check

Vitamin K1

15 mcg (19% DV)

✅ Within RDA (0.1× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)

RDA 0.12mg This product: 0.015mg

Calcium

250 mg (25% DV)

Phosphorus

120 mg (12% DV)

✅ Within RDA (0.2× RDA of 700 mg) 📚 12 studies (Tier A: 0, B: 3)

RDA 700mg This product: 120mg UL 4000mg

Boron

0.5 mg

📊 Market median: 3.0mg (58 products) 📚 2 studies — no high-quality reviews

This product: 0.5mg UL 20mg

Other Ingredients

Cellulose Hydroxypropyl Methylcellulose Croscarmellose Sodium Vegetable Stearate Silica Water Polyethylene Glycol Magnesium Silicate (poly) ethenol Polysorbate 80

Label Claims — Verification

❓ Nutrient

❓ All Other

All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Usage: As a dietary supplement, adults take 1 tablet daily with food or as directed by your healthcare professional.

⚠️ Warnings & Precautions

WARNING: This product contains Vitamin K, which intereferes with the prescription drugs Coumadin and Warfarin. Do not take this if taking either of these drugs.

KEEP OUT OF REACH OF CHILDREN.

Tamper resistant package, do not use if outer seal is missing.

🧪 Formulation Notes

Osteo-Guard(R) provides calcium and phosphate from young bovine bone (as microcrystalline hydroxyapatite), trace minerals, bone matrix proteins, amino acids and glycosaminoglycans in their natural forms and physiologic ratios found in whole bone.

WARNING: This product contains Vitamin K, which intereferes with the prescription drugs Coumadin and Warfarin.

Additional Information

.For optimal storage conditions, store in a cool, dry place. (59(0) - 77(0)F/15(0) - 25(0)C) (35-65% relative humidity)

OSG

Product Details

UPC / SKU 7 45287 04011 9

DSLD Entry Date 2014-03-25

Product Type Other Combinations

Form Tablet or Pill

Brand Douglas Laboratories

DSLD ID 31336

Data Updated 2026-04-11

Research Evidence

332 Research Sources

59 Avg Quality Score

220 Meta Analysis

56 Systematic Review

30 Rct

16 Clinical Trial

3 Guideline

3 Regulatory Source

1 Narrative Review

1 Other

1 Openfda Safety

A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI Cochrane

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI

A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2016

PubMed DOI

A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI

A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair

Meta Analysis The Cochrane database of systematic reviews 2025

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Meta Analysis The Cochrane database of systematic reviews 2018

PubMed DOI

A Antiplatelet agents and anticoagulants for hypertension

Systematic Review The Cochrane database of systematic reviews 2022

PubMed DOI

A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy

Meta Analysis The Cochrane database of systematic reviews 2012

PubMed DOI

A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation